Hepatitis E infection
Vincent C. Kuo, MD H epatitis E usually presents as a self-limiting viral hepatitis. It is not commonly seen in the United States and is more prevalent in endemic areas. Signs and symptoms are similar to those of other acute viral hepatitis infections. Here a case is presented of a man who recently returned from India and was found to have acute viral hepatitis E infection.
CASE PRESENTATION
A 63-year-old Indian man presented to the emergency department with fever, nausea, chills, and generalized abdominal pain that had been present for 2 weeks. Th e patient had been in India for the past 3 months and began to feel ill during the last week of his visit. He was seen by a local physician and was found to have abnormal liver function tests and was treated with sparfl oxacin and silibinin. Upon his return, the patient's symptoms persisted, with fevers up to 102°F, and he began to have emesis. He was admitted for further workup.
Th e patient had a past medical history of allergic rhinitis and gastroesophageal refl ux disease. He took omeprazole for his refl ux and had taken the sparfl oxacin and silibinin given to him while in India. He had no known drug allergies. He did have a signifi cant drinking history: in addition to having 3 to 4 drinks of brandy per day, he engaged in heavy binge drinking during his trip to India. He did not smoke or have a history of illicit drug use.
Th e patient had a low-grade temperature of 100°F on admission with normal blood pressure and heart rate. On physical examination, he had signifi cant scleral icterus. His abdomen was soft and mildly distended with no appreciable ascites or hepatosplenomegaly. He had some generalized discomfort to deep palpation diff usely but no guarding or rebound tenderness. He had no spider angiomas, gynecomastia, or asterixis.
His admission laboratory values were signifi cant for a total bilirubin of 9.4 mg/dL with a direct bilirubin of 6.5 mg/dL, alkaline phosphatase of 198 U/L, aspartate aminotransferase (AST) of 560 U/L, and alanine aminotransferase (ALT) of 303 U/L. His complete blood count showed a white blood cell count of 11.8 K/uL, hemoglobin of 13.1 g/dL, hematocrit of 37.1%, and platelet count of 331 K/uL. Prothrombin time was 14.4 seconds with an international normalized ratio of 1.4.
Viral hepatitis serologies revealed IgG antibodies to hepatitis A virus, a positive hepatitis B surface antibody with negative core antibody, and a negative hepatitis C antibody and polymerase chain reaction (PCR) test. Th e patient was found to have positive hepatitis E IgM and IgG antibodies in a stool sample and was also positive for hepatitis E RNA on PCR. Abdominal Doppler sonography revealed patency of all hepatic vessels, a normal liver appearance, and no ascites. Th e patient was diagnosed with acute hepatitis secondary to hepatitis E virus and was treated with conservative measures in the hospital. He never developed any signs of fulminant hepatic failure and, at the time of discharge, his liver enzymes were normalizing and symptoms were improving.
DISCUSSION
Hepatitis E virus is a single-stranded RNA virus in the family Herpesviridae (1) . Th e fi rst documented infection was in 1955 in New Delhi, India, and the highest incidence of infection is in Asia, Africa, Central America, and the Middle East (2, 3). Hepatitis E is enterically transmitted, spread by contaminated water in endemic areas. Th e highest attack rates occur in adults between the ages of 15 and 40 (4) . Most cases in developed nations follow travel to areas that are endemic for the virus (5). In the United States, serologic evidence for hepatitis E has been as high as 21%, but most individuals have no clinical signs of acute hepatitis infection. One possibility for this discrepancy is that in the United States, the exposure is due to the less virulent genotype 3 of the hepatitis E virus (6) . Th is has been linked to swine and is considered to be a zoonotic infection.
Hepatitis E infection presents similarly to other forms of acute viral hepatitis. Patients may be jaundiced from cholestasis and have generalized malaise, anorexia, nausea, vomiting, abdominal pain, and fever. Th e incubation period for hepatitis E infection can range from 15 to 60 days. If fulminant hepatitis occurs, the fatality rate ranges from 0.5% to 3%. Laboratory values usually refl ect an elevated bilirubin, AST, and ALT. Th ese levels can remain elevated up to 6 weeks after onset of illness (7) (8) (9) .
Certain patient populations can have more adverse clinical courses or are at higher risk for hepatitis E infection. It is known that pregnancy carries a higher risk of fulminant hepatic failure for reasons not well understood. Patients who are immunosuppressed appear to have a higher incidence of infection and can evolve to chronic hepatitis E infection, which has otherwise not been described (10) (11) (12) .
Hepatitis E infection is best diagnosed by detection of viral RNA by PCR or by IgM antibodies to the virus found in serum or stool samples (13) . Th e incubation period after exposure is 4 to 5 weeks, and patients can have persistent viremia for up to 4 months (14) . IgM antibodies appear in the early phase and gradually disappear over several months. Th e IgG antibodies appear after the IgM response and in some case reports can persist for as long as 14 years (15) .
Treatment of acute hepatitis E is supportive and involves watching for signs of hepatic failure. Th ere have been case reports of using ribavirin as a potential treatment for acute hepatitis E infection and even chronic infection (16) . Pegylated interferon has also been shown to be successful in treating hepatitis E infection in some liver or kidney transplant patients (17, 18) . In certain settings, a hepatitis E vaccine can be used to prevent infection (19) .
